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Background: Splenectomy is the most effective treatment for patients with primary immune thrombocytopenia
(ITP) who fail to respond to steroid therapy. Thus far, there is no effective means to predict the long-term
haematological response of the procedure. The purpose of this study was to identify serum biomarkers as
predictors of long-term response based on a proteomics approach.
Methods: The serum samples of ITP patients were collected before splenectomy and seven days after surgery. After
depletion of the abundant serum proteins, pooled preoperative serum samples from four responders to
splenectomy, four nonresponders and four healthy controls were subjected to two-dimensional gel electrophoresis
(2-DE). Nine protein spots with at least a five-fold alteration in expression between responders and nonresponders
were all identified as haptoglobin (Hp) by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF)
mass spectrometer (MS) analysis. The validation of serum Hp expression was performed using enzyme-linked
immunosorbent assays (ELISA) in thirty-seven responders, thirteen nonresponders and twenty-one healthy controls.
Results: The preoperative serum levels of Hp in the nonresponders (925.9 ± 293.5 μg/ml) were significantly lower than
those in the responders (1417.4 ± 315.0 μg/ml, p <0.001) and the healthy controls (1409.1 ± 354.2 μg/ml, p <0.001),
while there was no significant difference between the latter two groups. The postoperative serum levels of Hp in
responders and nonresponders were (1414.1 ± 225.0 μg/ml) and (952.9 ± 202.4 μg/ml), respectively. There were no
significant differences between the serum Hp levels before and after surgery in both responders and nonresponders
(p>0.05). The preoperative serum levels of Hp did not significantly correlate with preoperative platelet count of the
same blood samples (r = 0.244, p = 0.087), while it positively correlated with postoperative peak platelet count
(r = 0.622, p < 0.001). The optimal cutoff value of preoperative serum Hp levels (1173.80 μg/ml) derived from the
receiver operating characteristic (ROC) curve led to 78.4% sensitivity and 84.6% specificity.
Conclusions: These results suggest that serum Hp levels may serve as a favourable predictor for the long-term
response to splenectomy in ITP and may help to understand the pathophysiological differences between responders
and nonresponders.
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Primary immune thrombocytopenia (ITP), also known
as primary immune thrombocytopenic purpura or idio-
pathic thrombocytopenic purpura, is an immune-
mediated acquired disease characterised by low platelet
counts and bleeding complications in children and
adults [1]. Patients with platelet counts persistently
lower than 30 × 109/L are at risk for life-threatening
bleeding. The main mechanisms of ITP are anti-platelet
autoantibody-mediated platelet destruction and inhib-
ition of thrombopoiesis [2]. Other mechanisms such as
abnormal T-helper cells type 1 (Th1) and type 2 (Th2)
responses, complement activation, and direct T-cell
cytotoxicity were also found in ITP patients [2].
The spleen has been considered the main site for the
autoimmune processes in ITP pathophysiology [3].
Splenectomy has proven to be a preferred treatment for
ITP patients who do not respond to glucocorticoid treat-
ment or continue to need high-dose glucocorticoids to
maintain a safe platelet count. The results of numerous
studies indicate that approximately two-thirds of adult
patients and 70 to 80 percent of children achieve a dur-
able response to splenectomy [1]. However, splenectomy
for ITP is often associated with the risk of major mor-
bidity and mortality, and the long-term haematological
outcomes of the procedure cannot be predicted through
routinely available measures [4]. Some studies reported
that several variables may predict a stable response to
splenectomy including younger age [5-7], previous
response to steroids [6,7] and postoperative peak platelet
count [8,9]. Other studies showed opposite results [10-
12]. Najean et al. found the site of autologous 111In-
labeled platelet sequestration to be a good prognostic
parameter [13]. However, the techniques of isotope
assessments are often qualitative, rather than quantita-
tive, and many patients with nonsplenic sequestration
also respond well to splenectomy [4]. Hence, the assess-
ments of platelet sequestration are not widely accepted.
The fear of failure to respond to the splenectomy ren-
ders many patients reluctant to undergo surgery and
haematologists hesitant to recommend the surgery.
Therefore, it is imperative to identify a preoperative
serum biomarker that can serve as a predictor of good
response to splenectomy and help patients and physi-
cians with the decision of using surgery to treat ITP.
In this study, we used two-dimensional gel electro-
phoresis (2-DE) technology coupled with matrix-assisted
laser desorption/ionisation time-of-flight (MALDI-TOF)
mass spectrometer (MS) analysis to identify differentially
expressed proteins in ITP patients with different
responses to splenectomy. The identified proteins were
further confirmed by enzyme-linked immunosorbent
assays (ELISA) to evaluate their values in predicting the
long-term response to splenectomy.Methods
Patients and healthy controls
This study included fifty-eight patients (twenty males
and thirty-eight females; mean age 38.1 ± 15.6 years; age
range 16–70 years) undergoing laparoscopic splenec-
tomy for chronic ITP at the Department of Minimal
Invasive Surgery, the First Affiliated Hospital of Sun Yat-
sen University, between May 2007 and April 2011. All
patients recovered well without any major postoperative
morbidity. The diagnosis of ITP was made according to
the guidelines published by the British Committee for
Standards in Haematology General Haematology Task
Force [14]. Other possible causes of thrombocytopenia
were ruled out. Routine blood tests (including haemo-
globins, reticulocyte counts, bilirubin levels, and lactate
dehydrogenase) were performed for all patients enrolled
in this study. Direct Coombs testings had been done in
the patients presenting with anaemia. No evidence of
haemolysis was found in these patients and Evans syn-
drome was excluded from this corhort. The indications
for splenectomy in these patients included those did not
respond to steroids at all and/or the requirement of pro-
longed use of high dose steroids to maintain a platelet
count over 30×109/L. All patients received corticoster-
oids or immunosuppressive agent treatment until they
underwent laparoscopic splenectomy. The dosages of
steroids were then reduced gradually after surgery. The
blood samples of ITP patients were collected before
splenectomy and seven days after surgery. None of the
patients enrolled in this study received any platelet
transfusions, intravenous immunoglobulin or anti-RhD
immunoglobulin (anti-D) treatments for at least two
weeks before the collection of the preoperative blood
samples. Twenty-five age- and sex-matched healthy sub-
jects served as the controls. The study was approved by
the Ethical Committee of the First Affiliated Hospital of
Sun Yat-sen University. Informed consent was obtained
from each patient and healthy subject.
Definition of long-term response to splenectomy
All of the patients were followed up after splenectomy
throughout the study. In this study, we adopted the def-
inition of haematological outcome suggested recently by
the international working group [1]. Complete response
(CR) was defined as a platelet count ≥ 100×109/L and
the absence of bleeding. Response (R) is defined as any
platelet count between 30 and 100×109/L and at least a
two-fold increase in the baseline count and the absence
of bleeding. No response (NR) is defined as any platelet
count lower than 30×109/L or less than a two-fold in-
crease in the baseline platelet count or the presence of
bleeding. In this study, the long-term response to splen-
ectomy was defined as a complete response or response
from twelve months to the last follow-up without any
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were subdivided into the responder (CR+PR) group
(n=41) and the nonresponder (NR) group (n=17)
according to the long-term follow-up results.Serum sample preparation
Fresh whole blood samples were collected during a fast-
ing state in the early morning. All samples were trans-
ported on ice and centrifuged immediately at 3000 g for
15 min at 4°C. The supernatants were divided into 500 μl
aliquots and stored at −80°C until further analysis. Blood
samples from four patients in the responder group, four in
the nonresponder group, and four healthy controls were
used for the screening study. The serum samples from the
other thirty-seven responders, thirteen nonresponders,
and twenty-one healthy controls were used for the valid-
ation study.
Highly abundant proteins in serum were depleted
using a Proteoprep Blue Albumin and IgG Depletion Kit
(Sigma-Aldrich, Missouri, USA) according to the manu-
facturer’s instructions. The final protein concentration
was detected using the Bio-Rad Protein Assay technique.Two-dimensional electrophoresis and image analyses
Isoelectric focusing (IEF) was performed on an Ettan
IPGphor III IEF System (Amersham Bioscience, Uppsala,
Sweden) at 20°C. Immobiline DryStrips (18 cm long, pH
4–7) (Amersham Bioscience, Uppsala, Sweden) were
rehydrated actively at 30 V for 12 h with 750 μg
of depleted serum protein that was premixed with
rehydration buffer containing 7 M urea, 2 M thiourea,
2% 3-[(3-cholamidopropyl) dimethylammonio]-1-propa-
nesulfonate (CHAPS), 0.5% (v/v) ampholytes (pH 4–7),
20 mM dithiothreitol (DTT) and a trace of bromophenol
blue (making the final volume of 350μl). IEF was con-
ducted with gradient voltages of 200 V for 1 h, 1000 V
for 1 h, a 3 h linear ramp up to 10,000 V, and final fo-
cusing at 10,000 V for a total of 110,000 Vh. The immo-
bilized pH gradient (IPG) strips were equilibrated in
buffer 1 (75 mM Tris–HCl, pH 8.8, 6 M urea, 30% (v/v)
glycerol, 2% (w/v) sodium dodecyl sulfate (SDS), 1% (w/v)
DTT and a trace of bromophenol blue) for 15 min and
then subsequently alkylated in buffer 2 (75 mM Tris–HCl
pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 2.5%
(w/v) iodoacetamide and a trace of bromophenol blue) for
15 min. The IPG strip was then transferred to a 12.5%
SDS polyacrylamide gel, and the second dimensional sep-
aration was performed in an Ettan DALT six Electrophor-
esis Unit (Amersham Bioscience, Uppsala, Sweden) with
the power set at 1 w/gel for 1 h followed by 15 w/gel until
the tracking dye migrated to within 1 cm of the bottom of
the gel at 15°C. The gels were stained with colloidal coo-
massie as described in the manual.The 2-DE gel images were analysed using Image Master
2D Platinum 6.0 software (Amersham Bioscience, Upp-
sala, Sweden). The relative volumes of spots were used for
comparison between two patient groups. Our study
mainly focused on the highly differentially expressed pro-
teins whose expressions were strongly associated with re-
sponse to splenectomy in ITP patients. As described by
Zhang et al. [15], the criterion for highly differentially
expressed protein was also set as at least a five-fold change
in spot volume between the two matched sets in our
study. Only those highly differentially expressed protein
spots (at least five-fold alterations in expression in respon-
ders versus nonresponders) were chosen for further ana-
lysis by MALDI-TOF/TOF MS.
In-gel digestion and MALDI-TOF/TOF MS analyses
Protein spots of interest were excised manually from
2-DE gels, destained with 15 mM potassium ferricyan-
ide and 50 mM sodium thiosulfate, and subsequently
dehydrated in 100% acetonitrile. Each sample was
then treated with 2 μl (25 ng/μl) of modified porcine
trypsin in 25 mM ammonium bicarbonate (pH 8)
overnight at 37°C. The trypsin solutions were col-
lected for mass spectrometry analysis.
Protein identification was performed with an Ultraflex
III mass spectrometer (Bruker Daltonics, Bremen, Ger-
many) and operated in the positive ion reflectron mode. A
saturated solution of α-cyano-4-hydroxycinnamic acid in
50% acetonitrile and 0.1% trifluoroacetic acid was used as
the matrix. A standard peptide mixture with a mass range
800–4000 Da (Bruker Daltonics, Germany) was used for
external calibration. The subsequent MS/MS analysis was
performed in a data-dependent manner, and the five most
abundant ions fulfilling certain pre-set criteria were sub-
jected to LIFT for a post-source decay analysis.
Peptide mass fingerprints (PMFs) and MS/MS analyses
were searched by the BioTools software (version 3.0,
Bruker Daltonics, Germany) against the SwissProt pro-
tein database. The search parameters were as follows:
trypsin digestion with maximum one missed cleavage;
carbamidomethylation of cysteine as fixed modification
and oxidation of methionine as variable modification;
peptide mass tolerance, ± 100 ppm; fragment mass toler-
ance, ± 0.5 Da; peptide charge, +1; and monoisotopic
mass. Protein identifications were accepted when the
peptide score was higher than the threshold value
(p<0.05), and manual interpretation was used to confirm
agreement between the spectra and peptide sequence.
Validation of identified proteins by ELISA
To validate the haptoglobin (Hp) expression in serum,
serum samples from ITP patients and healthy controls
were analysed by ELISA. The Hp levels of serum sam-
ples collected seven days after surgery were also
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serum were determined using an AssayMax human Hp
ELISA kit according to the manufacturer's protocol
(Assaypro, Winfield, MO, USA).Statistical analysis
Statistical analysis was carried out using SPSS 16.0 for
Windows software (SPSS Inc., Chicago, IL, USA). Com-
parisons of gender and previous response to steroids be-
tween two patient groups were carried out using the
chi-square test. Continuous variables were expressed as
mean ± standard deviation (SD). Comparisons were per-
formed using the Mann–Whitney test between two in-
dependent groups, or one-way ANOVA followed by the
least-significant difference test for three groups. The
changes of the serum Hp levels before and after surgery
in responders and nonresponders were analysed with
Wilcoxon test. Correlation between parameters was
assessed by calculating the Pearson’s correlation coeffi-
cient. Receiver operating characteristic (ROC) curve was
used to evaluate the predictive value of preoperative
serum levels of Hp for long-term haematological out-
comes of surgery. The area under the curve (AUC) with
a 95% confidence interval (CI) was computed. Sensitivity
and specificity were calculated according to different
cutoff values. A P value less than 0.05 was considered
statistically significant.Results
Study population
Table 1 summarises the baseline clinical characteristics
of fifty-eight patients. There were no significant differ-
ences in the age, gender, previous response to steroids,
disease duration before the surgery, preoperative platelet
count or the duration of follow-up between the re-
sponder and nonresponder groups. However, a signifi-
cantly higher postoperative peak platelet count was
observed in the responders compared to the nonrespon-
ders (P<0.001).Table 1 Baseline Characteristics of Patients
Variables Respond
(n=41)
Age, year 36.4 ± 14
Gender (male/female) 13/28
Previous response to steroids (response/resistance) 21/20
Disease duration, months 35.9 ± 34
Preoperative platelet count (×109/L) 29.9 ± 28
Postoperative peak platelet count (×109/L) 439.9 ± 1
Follow-up, months 34.4 ± 13Identification of Hp by 2-DE separation and MALDI-TOF/
TOF-MS analyses
Pooled preoperative serum proteins from four patients
in the responder group, four in the nonresponder group,
and four healthy controls were subjected to 2-DE separ-
ation. Two-dimensional electrophoresis was performed
four times per sample to minimise gel-to-gel variations.
Figure 1A, 1B, and 1C show original 2D gel images for
all samples of the three groups and identify a number of
distinct protein spots. The enlarged images of regions
1–3 in the corresponding 2-DE gels reveal significant
differential changes for some of the potential novel bio-
markers (spots a-i, Figure 1D). By quantitative compari-
son of spot volumes, nine protein spots (spots a-i,
Figure 2) were found to be down-regulated more than
five-fold in the nonresponders when compared with the
responders.
These nine protein spots were then excised from the
gels and analysed by MALDI-TOF/TOF-MS. The results
revealed that all of these protein spots were identified as
Hp with different isoelectric points (pI) and molecular
weights (MW) (Table 2). Figure 3 is a representative
MALDI-TOF peptide mass fingerprint spectrum of
trypsin-digested spot b, which was remarkably down-
regulated in the nonresponders and was later identified
as Hp.
Decreased expression of Hp in the serum of
nonresponders
ELISA was further performed to validate the results of
the 2-DE. As shown in Figure 4, the preoperative serum
levels of Hp in thirty-seven responders, thirteen nonre-
sponders, and twenty-one healthy controls were (1417.4 ±
315.0 μg/ml, 95% CI: 1312.3-1522.4 μg/ml), (925.9 ± 293.5
μg/ml, 95% CI:748.5-1103.2 μg/ml) , and (1409.1 ± 354.2
μg/ml, 95% CI: 1247.9-1570.3 μg/ml), respectively. One-
way ANOVA analysis showed that the preoperative
serum levels of Hp in the nonresponders were sig-
nificantly lower than those in the responders (p < 0.001)
and healthy controls (p < 0.001). There was no signifi-
cant difference in the preoperative serum levels of Hper group Nonresponder group
(n=17)
P value
.9 42.3 ± 16.9 0.203
7/10 0.490
5/12 0.128
.1 30.9 ± 31.4 0.851
.4 18.0 ± 10.4 0.090
71.0 201.1 ± 132.6 <0.001
.4 35.3 ± 13.9 0.824
Figure 1 Differentially expressed protein spots identified by 2-DE image analysis. The original 2-DE images representing all protein spots
present in serum samples from the nonresponder group (A), the responder group (B), and the healthy control group (C). The enlarged images
(D) showing the magnified regions 1–3 of the corresponding 2-DE gels. Nine identified protein spots (a-i, arrows showing the corresponding
locations) with significantly differential expressions among the three groups were visualised. Protein spots a to i showed obviously decreased
expressions in the nonresponders compared with the responders and healthy controls.
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The postoperative serum levels of Hp in the responders
and the nonresponders were (1414.1 ± 225.0 μg/ml, 95%
CI: 1339.1-1489.1 μg/ml) and (952.9 ± 202.4 μg/ml, 95%
CI: 830.6-1075.2 μg/ml), respectively. There were no sig-
nificant differences between the serum Hp levels before
and after surgery in both responders and nonresponders
(p>0.05). Pearson’s correlation analysis showed that the
preoperative serum levels of Hp did not significantly cor-
relate with preoperative platelet count of the same blood
samples collected for this study in ITP patients (r = 0.244,
p = 0.087), while a positive correlation was found between
the preoperative serum Hp levels and postoperative peak
platelet count (r = 0.622, p < 0.001).
Predictive value of preoperative serum levels of Hp
Using the ROC curve method, we evaluated the predict-
ive value of the preoperative Serum Hp levels for long-
term response to splenectomy. As showed in Figure 5,
AUC was 0.867 (95% CI: 0.764-0.970), indicating thatthe preoperative Serum levels of Hp was a good pre-
dictor to differentiate responders from nonresponders.
Table 3 showed the sensitivity and specificity of different
cutoff values. Based on the maximum Youden index
(sensitivity+specificity-1), the optimal cutoff value from
the ROC curve, Hp ≥ 1173.80 μg/ml, was chosen. When
this value was set, the sensitivity was 78.4% and the spe-
cificity was 84.6% for discriminating responders from
nonresponders.
Discussion
Comprehensive analysis of the changes in serum pro-
teomes are an important part of broad evaluations of the
diagnosis, prognosis and therapeutic response of pro-
gressing diseases, such as autoimmune disorders, cardio-
vascular diseases, and cancers. With commonly used
proteomic approaches, it is feasible to discover differen-
tially expressed proteins in samples from patients that
are likely to be involved in the autoimmune process or
serve as biomarkers that correlate with disease or
Figure 2 3-D view of highly differentially expressed proteins. The computational analysis of the images with Image Master 2D Platinum 6.0
software allowed for the detection of protein volumes. Significant changes of more than 5-fold were found in the protein spots (spots a to i) of
the magnified regions 1–3 of the corresponding 2-DE gels among the nonresponder group (A), the responder group (B), and the healthy control
group (C). The differentially expressed proteins were down-regulated in the nonresponders compared with the responders and healthy controls.
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proteomic-based study for biomarkers has been reported
in ITP patients. In the study, one-dimensional gel elec-
trophoresis was used to separate serum proteins in ITP











a Haptoglobin P00738 MS,MS/MS 84,92 1
b Haptoglobin P00738 MS,MS/MS 67,116 1
c Haptoglobin P00738 MS,MS/MS 103,90 1
d Haptoglobin P00738 MS,MS/MS 92,100 1
e Haptoglobin P00738 MS,MS/MS 109,66 1
f Haptoglobin P00738 MS/MS 46 2
g Haptoglobin P00738 MS/MS 129 1
h Haptoglobin P00738 MS/MS 94 2
i Haptoglobin P00738 MS/MS 54 1healthy controls [18]. Quantification of the serum pro-
teins identified by liquid chromatography-tandem mass
spectrometric (LC-MS/MS) analysis showed that the
serum ceruloplasmin levels in ITP patients were statisti-





MW (kD)/pI Fold change (responder/
nonresponder, n=4)
2,2 34%,5% 42.1/5.08 8.11
2,3 33%,8% 42.2/5.21 5.94
0,2 32%,6% 42.0/5.37 5.50
2,2 32%,6% 39.1/5.21 5.60





Figure 3 Representative MALDI-TOF peptide mass fingerprint spectrum of spot b. After trypsin digestion, the resulting peptides were
analysed by MALDI-MS and MS/MS analyses. Peptide mass fingerprints (PMFs) data were searched against the database of SwissProt by BioTools
3.0 software. The protein with molecular mass of approximately 42 kDa was identified as haptoglobin (Hp) by the sequence analysis.
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markers predicting long-term response to splenectomy in
ITP patients, the present study carried out a comparative
proteomics analysis with 2-DE and MS on the sera from
the responders, nonresponders and healthy controls. Nine
protein spots that were differentially expressed by at leastFigure 4 The preoperative serum level of Hp was validated by
ELISA. One-way ANOVA analysis showed significant difference of
preoperative serum Hp expressions among the three groups. The
preoperative serum levels of Hp in thirteen nonresponders was
significantly lower than that of thirty-seven responders (p <0.001)
and twenty-one healthy controls (p <0.001). No significant difference
was seen between the responders and healthy controls (p > 0.05).
Figure 5 Receiver operating characteristic (ROC) curve for the
preoperative serum level of Hp in responders versus
nonresponders. The area under curve (AUC) value of the
comparison between groups was 0.867 (95% CI: 0.764-0.970). The
optimal cutoff value of preoperative serum Hp levels (1173.80 μg/
ml) derived from the ROC curve led to 78.4% sensitivity and 84.6%
specificity.
Table 3 Sensitivity and specificity for the preoperative
serum Hp levels at different cutoff values
Cutoff (μg/ml) Sensitivity (%) Specificity (%) Youden index
816.42 100 38.5 0.385
911.41 91.9 46.1 0.380
1026.61 86.5 53.8 0.403
1073.74 83.8 61.5 0.453
1119.61 81.1 76.9 0.580
1173.80 78.4 84.6 0.630
1265.94 62.2 92.3 0.545
1485.29 54.1 100 0.541
Zheng et al. Journal of Translational Medicine 2012, 10:208 Page 8 of 10
http://www.translational-medicine.com/content/10/1/208five-fold between the responder and nonresponder sam-
ples were further analysed with MS/MS. All of the spots
were identified as Hp by the peptide sequence analysis.
Although the measurement of serum ceruloplasmin levels
was found to be useful for the diagnosis of ITP in the re-
port mentioned above, we did not identify ceruloplasmin
as a highly differentiated expressed protein between
responders and nonresponders in this study.
Hp is an acute phase protein that is synthesised pre-
dominately in the liver by hepatocytes. The major in-
ducer of the expression of Hp is IL-6, which is produced
through the activities of the primary cytokines TNF-α
and IL-1 [19]. The serum levels of Hp remains fairly
constant in any given individual; therefore, the observa-
tion of a marked change in serum Hp expression has
clinical significance [20]. Hp consists of two different
polypeptide chains, α chain and β chain. There is only
one type of β chain with a MW of approximately 40
kDa. However, the α chain is represented by two iso-
forms, α-1 and α-2, with the α-1 isoform being approxi-
mately 9 kDa and the α-2 being 16 kDa in MW [21].
After chemical reduction of Hp, these polypeptide chains
can be clearly revealed in the images of gel electrophor-
esis [21]. In this study, five protein spots with MW of
38.7 - 42.2 kDa, shown in region 1 of the 2-DE images,
were identified as the β chain of Hp. While three protein
spots in region 2 (MW 16.9 - 17.1 kDa) and one protein
spot in region 3 (MW 11.9 kDa) represented the α-2 and
α-1 isoforms of Hp.
Hp has been proven to modulate both innate and
adaptive immune responses in several aspects. Th1 and
Th2 play a crucial role in the pathogenesis of auto-
immune diseases [22]. Studies performed both in vitro
and in vivo indicate that Hp exhibits a significant modu-
lating impact on the Th1/Th2 balance via an inhibitory
effect on Th2 cytokine release and therefore promotes a
dominant Th1 cellular response [23,24]. Hp supports
proliferation and functional differentiation of B and T
cells as part of homeostasis and in response to antigen
stimulation. Analysis of blood from Hp-deficient miceshowed a significant reduction in B and T lymphocytes,
and the relative number of splenic monocytes and den-
dritic cells appeared elevated with respect to wild-type
mice [25]. A more recent study showed that Hp-
deficient mice facilitate the development of autoimmune
disease of central nervous system, which is associated
with the enhanced production of several inflammatory
cytokines in the spinal cord [26]. Hp is characterised by
molecular heterogeneity, with three major phenotypes:
Hp 1–1, Hp 2–2, and the heterozygous Hp 2–1. The Hp
2–2 genotype was associated with decreased serum con-
centrations of Hp. A significant over-representation of
the Hp 2–2 genotype has been shown in human im-
mune disorders, such as rheumatoid arthritis, diabetes
mellitus type 2, and inflammatory bowel diseases [27].
Taken together, these studies suggest that Hp may play
an important role in the pathogenesis and clinical course
of autoimmune diseases through various immunomodu-
latory effects. To date, very few studies in the current lit-
erature focused on the issue of the serum Hp expression
in ITP patients. A recent study found that abnormally
low levels of free serum Hp were present in eleven out
of thirty paediatric patients with ITP [28]. The authors
considered Hp as a sensitive indicator of haemolysis and
presumed that patients with low levels of serum Hp may
develop autoimmune haemolytic anaemia in long-term
follow-up studies. Until now, the pathophysiological
roles of Hp in ITP were poorly understood.
Recent proteomic studies showed that Hp served as an
important biomarker in some autoimmune diseases.
Increased protein levels of Hp were found in the cere-
brospinal fluid from patients with Guillain-Barré syn-
drome, which is an acute inflammatory autoimmune
disorder in the peripheral nervous system [29,30]. Other
studies reported that elevated serum levels of Hp corre-
lated with higher disease activity in systemic lupus
erythematosus and active Behcet’s disease [31,32]. In the
present study, we studied the differentially expressed
proteins in the serum of ITP patients with different
responses to splenectomy using a comparative proteo-
mics approach. Hp was identified as a highly differen-
tially expressed protein between nonresponders and
responders. Further validation by ELISA showed that the
preoperative serum levels of Hp in the nonresponders
were significantly lower than those in the responders
and healthy controls. No statistical differences of pre-
operative serum Hp expression were observed between
the responders and healthy controls. The results indicate
that the preoperative serum levels of Hp may serve as an
important predictor of long-term haematological re-
sponse to splenectomy in ITP patients. Patients with
lower preoperative serum levels of Hp tend to have a
worse response to surgery when compared with those
with higher preoperative serum levels. The ROC curve is
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biomarker. The ROC curve analysis showed that AUC of
the preoperative serum Hp levels reached 0.867, which
means that the preoperative serum Hp levels can be
used as a potential predictive biomarker. The Youden
index has been demonstrated to be a preferred means of
identifying the optimal cutoff value from the ROC curve
[33]. Therefore the optimal cutoff value of the preopera-
tive serum Hp levels (1173.80 μg/ml) was identified
based on the the maximum Youden index in this study.
At this cutoff value, the sensitivity was 78.4% and the
specificity was 84.6%. The present study also found that
the serum Hp levels did not change seven days after sur-
gery in both responders and nonresponders. To the best
of our knowledge, this is the first paper reporting a po-
tential serum biomarker for predicting the long-term re-
sponse to splenectomy in ITP patients. However,
potential limitations of this study must be considered.
While the removal of abundant serum proteins would
facilitate the discovery and detection of less abundant
proteins, including disease associated markers. It should
be noted that this technique remains controversial in
biomarker discovery, as it may also remove other pos-
sibly more interesting proteins bound to the abundant
proteins[34]. Since relapses of ITP may occur even two
years after splenectomy, further studies with larger sam-
ple size and long-term follow-up are needed to confirm
our findings. Evans syndrome which links to low serum
level of Hp and poor response to splenectomy should be
strictly excluded from the study.
Conclusions
Our previous study found that the postoperative peak
platelet count was closely correlated with the long-term
response of splenectomy in ITP patients [35]. Similar
results were also shown in this study. However, this vari-
able can only be obtained after surgery and is of no use
for making the decision of therapeutics. The present
study demonstrates that by using a proteomic approach,
we are able to identify Hp as a potential serum bio-
marker, which may serve as a major predictor of long-
term response to splenectomy in ITP patients. The pre-
operative serum levels of Hp were also shown to be
positively correlated with postoperative peak platelet
count in ITP patients. These findings may be critical for
providing new insights into the pathogenic mechanisms
of ITP and optimising the strategic choice of surgical
intervention. Further research investigating the biology
of Hp would help to understand the pathophysiological
differences between responders and nonresponders.
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